Capricor Therapeutics (CAPR) Stock Price, News & Analysis

Company Overview

Capricor Therapeutics, Inc. is a biotechnology company focused on developing cell- and exosome-based therapies for serious diseases. The company’s programs are designed to use regenerative medicine and targeted delivery technologies to address conditions with limited treatment options.

Its leading therapeutic candidate is deramiocel, also known as CAP-1002, an allogeneic cell therapy derived from cardiosphere-derived cells. The program has been studied primarily for Duchenne muscular dystrophy, a genetic disorder that causes progressive muscle weakness and cardiac complications. Capricor is also developing an exosome-based platform intended to deliver therapeutic proteins, nucleic acids and other biological materials to specific tissues.

Capricor was founded in 2005 and is headquartered in Beverly Hills, California. The company’s research and development activities are primarily conducted in the United States, with its therapies intended for potential use in global markets subject to regulatory approval. Capricor is led by Linda Marbán, Ph.D., who serves as president and chief executive officer and has a background in cardiovascular regenerative medicine and cell-therapy research.

Key Stats

• Today's Range: $8.82 to $9.79
• 50-Day Range: $3.85 to $22.50
• 52-Week Range: $2.96 to $40.37
• Volume: 3.94 million shs
• Average Volume: 3.07 million shs
• Market Capitalization: $547.67 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $30.25
• Consensus Rating: Hold

Capricor Therapeutics Stock Analysis - MarketRank™

Capricor Therapeutics scored higher than 57% of companies evaluated by MarketBeat, and ranked 432nd out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Hold

Consensus Rating

Capricor Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 5 buy ratings, 6 hold ratings, and 1 sell rating.

Upside Potential

Capricor Therapeutics has a consensus price target of $30.25, representing about 219.5% upside from its current price of $9.47.

Amount of Analyst Coverage

Capricor Therapeutics has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Capricor Therapeutics are expected to grow in the coming year, from ($1.71) to ($1.19) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Capricor Therapeutics is -3.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Capricor Therapeutics is -3.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Capricor Therapeutics has a P/B Ratio of 1.71. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

42.02% of the float of Capricor Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Capricor Therapeutics has a short interest ratio ("days to cover") of 1.99, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Capricor Therapeutics has recently increased by 24.94%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Capricor Therapeutics does not currently pay a dividend.

Dividend Growth

Capricor Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.08

News Sentiment

Capricor Therapeutics has a news sentiment score of 0.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 56 news articles for Capricor Therapeutics this week, compared to 9 articles on an average week.

Search Interest

Only 29 people have searched for CAPR on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

Only 7 people have added Capricor Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -13% compared to the previous 30 days.

Company Ownership

• Score: 1.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Capricor Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $759,158.00 in company stock.

Percentage Held by Insiders

9.20% of the stock of Capricor Therapeutics is held by insiders.

Percentage Held by Institutions

21.68% of the stock of Capricor Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 9/17/2026
• Next Earnings (Estimated): 11/09/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:CAPR
• CIK: 1133869
• Web: www.capricor.com
• Phone: 310-358-3200
• Fax: 415-875-7075
• Employees: 231
• Year Founded: 2005

Price Target and Rating

• Average Price Target for Capricor Therapeutics: $30.25
• High Price Target: $60.00
• Low Price Target: $2.00
• Potential Upside/Downside: +221.1%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.45)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$105.04 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -56.60%
• Return on Assets: -43.97%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.35
• Quick Ratio: 7.35

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.53 per share
• Price / Book: 1.70

Miscellaneous

• Outstanding Shares: 58,139,000
• Free Float: 52,790,000
• Market Cap: $547.67 million
• Optionable: Optionable
• Beta: 0.72